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In recent years, attention has been drawn to
chemicals that exhibit estrogenic effects, and
screening programs have been initiated to
identify chemicals that act as endocrine dis-
ruptors. Most attention has focused on
industrial xenobiotics, herbicides, and pesti-
cides (1,2), but many naturally occurring
compounds are also potential endocrine dis-
ruptors, including plant-derived phytoestro-
gens. However, estimating the effects of
phytoestrogens is complex because they can
be more or less estrogenic, possess an aro-
matase inhibitory effect, inhibit other
enzymes involved in steroidogenesis, inhibit
tyrosine kinases, and have other properties as
well (3,4). Moreover, the bacterial flora in
the gut affects the metabolism of phytoestro-
gens, and the actual content of phytoestro-
gens in a plant is affected by a variety of
factors, including stress (5). Combined,
these complications make it difﬁcult to esti-
mate exactly the actual exposure to phyto-
estrogens, as well as the outcome of the
exposure.
Although most attention has been on
compounds that directly interact with the
estrogen receptors, chemicals can also affect
the endocrine system by interfering with the
synthesis or metabolism of steroid hor-
mones, for example, by inhibiting inactiva-
tion of estradiol by estrogen sulfotransferases
(6). Another obvious target is the enzyme
cytochrome P450arom (aromatase), which
catalyzes the conversion of testosterone to
17β-estradiol and ∆4-androstenediol to
estrone, which can be further processed to
17β-estradiol by P450c17 (17β-hydroxy-
steroid dehydrogenase) (7). That the aro-
matase plays a crucial role in the synthesis
and availability of the female sex hormone
17β-estradiol has been illustrated by the sex
reversal observed in developing turtle
embryos after treatment with an aromatase
inhibitor (8). Because sex hormones are
involved in regulatory processes throughout
a mammalian organism, the aromatase also
plays a critical role here, both in the ovary,
where most of the circulating estradiol in
premenopausal women is produced, and in
peripheral tissues that are the sites for estra-
diol synthesis in men and postmenopausal
women. The synthesis in peripheral tissues is
important because the endogenous, so-called
intracrine (7,9), 17β-estradiol production is
the main determinant of proliferation of
estrogen-dependent breast cancer cells and
breast carcinomas (10–12) as well as of many
natural effects of estrogens.
In this paper we present a novel assay
that estimates estrogenicity and aromatase
inhibitory effects of a compound simultane-
ously. The assay is based on human breast
cancer MCF-7 cells that routinely are used
in estrogenicity assays in which estrogenicity
of a compound can be measured by
increased cell proliferation or by the induc-
tion of estrogen-induced endogenous genes
(13–15). To assay aromatase inhibitors, we
modiﬁed the standard estrogenicity assay by
including testosterone in the media, which,
because of the endogenous aromatase activ-
ity in the MCF-7 cells (16–18), is con-
verted to 17β-estradiol that subsequently
induces an estrogenic response in the cells.
The response can be assayed by increased
proliferation or by the induction of the
estrogen-regulated pS2 mRNA (17). Thus,
compounds that inhibit the conversion can
be identified by a reduced estrogenic
response in the presence of testosterone and
the inhibitor. At the same time, reasonably
potent estrogens will induce a stronger
response than will the added testosterone,
and thus increase the estrogenicity also in
the presence of testosterone.
Materials and Methods
Cell culturing and exposure. The proce-
dures for cultivation and exposure have
been described previously (14,15). In brief,
we grew human breast cancer MCF-7 cells
in Dulbecco’s modified Eagle medium
(DMEM) containing 5% fetal bovine
serum, 1X nonessential amino acids, 2 mM
L-glutamine, 25 IU/mL penicillin–strepto-
mycin, and 1 nM insulin. DMEM and all
supplements were from Life Technologies
(Rockville, MD, USA). We transferred cells
to 25-mL cell culture flasks containing
steroid-depleted media, and after 6 days,
with change of media after 3 days, we
replaced the medium with steroid-depleted
media containing different concentrations
of the test compounds, with and without
100 nM testosterone added. After 24 hr, we
harvested the cells and isolated total RNA.
Test compounds. Test compounds were
17β-estradiol (Sigma-Aldrich, St. Louis,
MO, USA), testosterone (Sigma-Aldrich),
ICI 182.780 (AstraZeneca Pharmaceuticals,
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Endocrine disruptors can affect the endocrine system without directly interacting with receptors,
for example, by interfering with the synthesis or metabolism of steroid hormones. The aromatase
that converts testosterone to 17β-estradiol is a possible target. In this paper we describe an assay
that simultaneously detects aromatase inhibition and estrogenicity. The principle is similar to
that of other MCF-7 estrogenicity assays, but with a fixed amount of testosterone added. The
endogenous aromatase activity in MCF-7 cells converts some of the testosterone to 17β-estradiol,
which is assayed by quantifying differences in the expression level of the estrogen-induced pS2
mRNA. Potential aromatase inhibitors can be identified by a dose-dependent reduction in the
pS2 mRNA expression level after exposure to testosterone and the test compound. Using this
assay, we have investigated several compounds, including synthetic chemicals and phytoestrogens,
for aromatase inhibition. The phytoestrogens, except genistein, were aromatase inhibitors at low
concentrations (< 1 µM) but estrogenic at higher concentrations (≥ 1µ M), resulting in U-shaped
dose–response curves. None of the tested synthetic chemicals were aromatase inhibitors. The low-
dose aromatase inhibition distinguished phytoestrogens from other estrogenic compounds and
may partly explain reports about antiestrogenic properties of phytoestrogens. Aromatase inhibi-
tion may play an important role in the protective effects of phytoestrogens against breast cancer.
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androstene-3,17-dione (4-OHA; Sigma-
Aldrich), Anastrozole (kindly provided by
AstraZeneca, Basel, Switzerland), biochanin
A (Apin Chemicals, Abingdon, UK), genis-
tein (Sigma-Aldrich), formononetin (Apin
Chemicals), naringenin (Sigma-Aldrich),
chrysin (Sigma-Aldrich), red clover flowers
[dried powder, suspended at 10% (v/w) in
ethanol; Naturdrogeriet, Aarhus, Denmark],
nonylphenol (technical grade; Sigma-Aldrich),
bisphenol A (Sigma-Aldrich), dibutylphthalate
(Sigma-Aldrich), and dieldrin (Sigma-
Aldrich). (Chemical structures of the com-
pounds are shown in Figure 1.) We tested
each compound in a range of concentrations
with and without 100 nM testosterone.
Quantitation of mRNA expression. We
analyzed differences in expression levels of
endogenous estrogen-regulated genes by
competitive polymerase chain reaction
(PCR) and displayed them as for differential
display reverse transcriptase PCR. We quan-
tified differences in expression levels by
phosphor imaging analysis of the polyacry-
lamide gels. All procedures related to com-
petitive PCR have been described previously
(14,19) and detailed manuals can be found
on the Internet (20). We determined the
estrogenic response by quantifying the levels
of pS2 mRNA (21), which served as a
marker for estrogenicity (14,15).
Statistical analysis. In a pilot experiment
using two independent samples for each data
point, some phytoestrogens showed a U-
shaped dose–response curve. To allow statis-
tical analysis and verification, we repeated
selected experiments with four independent
samples at each concentration. Because the
U-shaped dose–response curves were quite
surprising, we designed the new set of exper-
iments to confirm or reject the hypotheses
generated from the results of the pilot exper-
iment. The two-stage procedure, involving a
pilot study in the first stage and the main
experiments in the second stage, implied
that the analysis of the results from the main
experiments involved testing a prespecified
hypothesis, and therefore no multiple testing
problems need to be considered. All curves
shown with error bars represent experiments
with four independent samples at each data
point. All other curves represent data from
the pilot experiments with only two inde-
pendent samples at each concentration,
except for the reference compound (testos-
terone), which in all experiments represents
four independent measurements. To adjust
for lane-to-lane variation, we normalized
each analysis as described previously (14).
This involved first subtracting the back-
ground level (the reading in the lane at a
position where no band is present) followed
by division with the background level [nor-
malized measurement = (“value of band” –
background) ÷ background]. Because the
normalized measurements varied with the
level of the normalized measurements, we
used a logarithmic transformation. This
both corrected for the heteroskedacity and
provided a better approximation to normal-
ity of the model residuals from the subse-
quent analysis. Normalization by simple
division of the measurements by the back-
ground (i.e., without first subtracting the
background) gave similar results. 
We performed the statistical analysis of
the dose–response relationship for each com-
pound separately, using a classic analysis of
variance (ANOVA) for comparing mean
response levels between groups, here the
means of the normalized measurements for
the different concentrations of the com-
pounds. We made the response levels of the
different compounds comparable in the
analysis of each compound by using testos-
terone as the reference level. If the estimated
dose–response relationship was not distinctly
U-shaped, we used a trend test by entering
the logarithm of the dose as a covariate in
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Figure 1. Chemical structures of the compounds used in the study.the model. p-Values are based on F-tests in
the model. We conﬁrmed all dose–response
relationships by nonparametric Kruskal-
Wallis tests confirming that the results are
robust toward possible deviations from the
ANOVA assumption of normality.
Results
Establishment of aromatase inhibitor assay.
We tested human breast cancer MCF-7 cells
for aromatase activity by assaying the induc-
tion of the estrogen-regulated pS2 mRNA
after addition of testosterone to the cells.
Adding 100 nM testosterone to the culture
medium resulted in induction of the pS2
mRNA similar to the induction following
addition of 50–100 pM 17β-estradiol to the
medium (Figure 2) (14). Most likely, this was
caused by testosterone being aromatized to
17β-estradiol because the up-regulation could
be blocked completely by the potent antie-
strogen ICI 182.780 (Figure 2). Next, we
tested whether known aromatase inhibitors
could abolish the testosterone-mediated pS2
mRNA induction (Figure 3). Both 4-OHA
and Anastrozole dose-dependently reduced
the testosterone-induced pS2 mRNA expres-
sion level to a level similar to that in cells
treated with ICI 182.780 (Figures 2–4).
Neither 4-OHA nor Anastrozole alone inﬂu-
enced the expression level of the pS2 mRNA,
and these compounds did not reduce the
induction by 17β-estradiol, showing that they
do not possess estrogenic or antiestrogenic
activity (not shown). We concluded that
MCF-7 cells could be used for identifying
potential aromatase inhibitors because such
compounds will lead to a down-regulation
similar to that resulting from exposure to
Anastrozole and 4-OHA.
Testing compounds. We assayed a range
of compounds, including synthetic estrogenic
chemicals and phytoestrogens (Figure 1,
Table 1), in a pilot experiment with two sam-
ples per data point. From the observed
responses, we selected several compounds
for further analysis with four independent
samples per data point.
In the presence of testosterone, either the
synthetic chemicals had no effect (low-
potency compounds), or they slightly
increased the expression level of the pS2
mRNA (Figure 3, Table 1). In contrast, and
to our surprise, most of the phytoestrogens
reduced the level of the pS2 mRNA at con-
centrations below those where they showed
an estrogenic response (Figures 3 and 4). At
higher concentrations, the estrogenicity of
the phytoestrogens again increased the estro-
genicity in the cultures (Figures 3 and 4).
Because we measured aromatase inhibition
and estrogenicity simultaneously, the result-
ing curves were the sum of two curves, one
similar to that of Anastrozole showing
decreasing expression due to aromatase inhi-
bition, and one showing increasing expression
due to the estrogenicity of the phytoestrogens.
Combined, this resulted in U-shaped
dose–response curves (Figures 3 and 4). This
U-shaped dose response was most pro-
nounced with biochanin A, with an esti-
mated level of 97.2% (SE, 90.1–105.0%) of
the testosterone response at 1 nM, 64.5%
(SE, 59.8–69.7%) at 0.1 µM, and 109.5%
(SE, 102.0–117.5%) at 10 µM. The statisti-
cal signiﬁcance of the difference between the
response level at 1 nM and 0.1 µM concen-
trations gave a p-value of 0.00013. A similar
test of the difference between levels at 0.1
µM and 10 µM gave a p-value of 0.000003.
Genistein did not act as an aromatase
inhibitor in this assay (Figure 3), which
agrees with previous results, showing that
genistein is not an inhibitor of the human
aromatase enzyme (22). Similar results have
previously been reported for formononetin
(3), which, however, did act as an aro-
matase inhibitor in this study (Figure 4).
We found some compound-specific differ-
ences in the results; the most potent aro-
matase inhibitor was biochanin A, followed
by naringenin and chrysin, and we found
the smallest effect for formononetin (Figure
4), which agrees with previous studies (3).
Phytoestrogens are derived from various
plants, which often contain many different
forms. To analyze whether a plant product
(which includes different phytoestrogens)
showed the same response, we made a 10%
(w/v) ethanol suspension of dried red clover
ﬂowers and tested the extract. The resulting
dose–response curve was U-shaped, show-
ing that combined aromatase inhibition
and estrogenicity also is present in extracts
from plants.
Discussion
We modiﬁed the MCF-7 estrogenicity assay
to also test for potential aromatase inhibitors.
The resulting bioassay is based on features
that are inherent to the cells, and as such, it is
more “in vivo-like” than are standard estro-
genicity assays that measure only the estro-
genicity of a compound. The modiﬁcation is
important because the intracrine 17β-estra-
diol production in peripheral tissues, by
aromatization of androgens, is the only
17β-estradiol source in men and post-
menopausal women. In accordance, the
intracrine estradiol synthesis is the main con-
tributor to estrogen-dependent processes in
peripheral tissues, including bone growth
(23) and early artherogenesis (24). Moreover,
it is the main determinant for the prolifera-
tion of breast cancer cells in vivo (10–12).
Because this assay measures aromatase inhibi-
tion and estrogenicity simultaneously, it
should give a more realistic evaluation of the
effect of a given compound in peripheral tis-
sues in vivo. Similar in vitro MCF-7 cell-
based aromatase inhibitor assays have
previously been suggested (25), and prolifera-
tion of MCF-7 cells, transfected into nude
mice, is sensitive to aromatase inhibitors
(26). However, we found no reports on the
effects of phytoestrogens, in the presence of
androgens, on the proliferation of MCF-7
cells in vitro or in vivo.
When we tested phytoestrogens in our
assay, most of them reduced the estrogenicity
at low concentrations, despite their intrinsic
estrogenicity. The reduced estrogenicity at
low concentrations most probably was caused
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Figure 2. Induction of pS2 mRNA by testosterone
(T; 100 nM) and 17β-estradiol (E2) and reversal of
induction by the antiestrogen ICI 182.780 (100 nM).
BA, biochanin A (10 µM). All values represent the
average of four independent experiments; error
bars indicate SD. 
Figure 3. Expression levels of the estrogen-
induced pS2 mRNA in MCF-7 cells after incubation
with the indicated concentrations of the different
compounds in the culture media. All values are
shown as percentage relative to the response to
100 nM testosterone (T), which we set to 100%.
Each point represents the mean of four indepen-
dent samples; error bars indicate SEM. The p-val-
ues indicate the statistical significance of the
decline between the 1 nM and 0.1 µM data points
of the biochanin A plus testosterone curve and the
increase between 0.1 µM and 10 µM data points,
thus representing the U shape.
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Concentrationby the 104–105-fold difference in potency
between 17β-estradiol and the most potent
phytoestrogens (14,15). Because of the large
difference in potency, a small reduction in
the synthesis of 17β-estradiol resulted in a
much larger reduction of the expression level
of the pS2 mRNA than the potential increase
induced by the estrogenicity of the low con-
centration of phytoestrogens that was needed
to inhibit the aromatase. Nevertheless, with
regard to the estrogenic response of the cells,
most of the phytoestrogens acted as antiestro-
gens at low concentrations (they reduced the
estrogenic response), but they acted as estro-
gens at high concentrations, resulting in U-
shaped dose–response curves. To our
knowledge, this is the ﬁrst time that a simple
in vitro assay, based solely on functions that
are intrinsic to the cells, has shown a U-
shaped dose–response curve, and it demon-
strates that compounds, in a cellular context,
can have opposite effects at different concen-
trations. Interestingly, we observed U-shaped
dose–response curves only for phytoestro-
gens. None of the tested synthetic chemicals
showed aromatase inhibitory effects, suggest-
ing that phytoestrogens can have properties
that clearly distinguish them from other
estrogenic compounds (Figures 3 and 4,
Table 1).
Aromatase inhibition by relatively high
concentrations of phytoestrogens has previ-
ously been reported (3,22,27–30). However,
because of the relatively high IC50 values
(concentration that inhibits 50%) (in the
micromolar range), the low-dose inhibition
that we report was not evident from the
results of other aromatase inhibition assays
(3,22,30). Nevertheless, both our assays and
previous assays detected aromatase inhibitory
properties for chrysin, biochanin A, and
naringenin, whereas genistein was not an aro-
matase inhibitor in any of the assays using
human aromatases (3,22). Formononetin did
not act as an aromatase inhibitor in the assay
of Le Bail et al. (3); however, formononetin
was the least potent aromatase inhibitor in
our assay, and the divergent results could be
caused by a higher sensitivity of our assay
(Figure 4). Alternatively, Kao et al. (22) have
shown that a single amino acid substitution in
the active site of the human aromatase can
change its sensitivity to compounds and, for
example, make it sensitive to genistein. Thus,
the aromatase either in our cells or in the cells
used by Le Bail et al. (3) could have point
mutations. Moreover, the sequence in the
active site of aromatase enzymes differs
among species, and rodent (mouse and rat)
aromatases may actually be sensitive to genis-
tein because they have a different amino acid
in a position where changes in the human
aromatase resulted in sensitivity to genistein
(results not shown) (22).
Many reports have described estrogenic
effects and some also antiestrogenic effects of
phytoestrogens in vivo, and most of the
affected end points are most properly depen-
dent on their estrogenic properties, includ-
ing increased uterine and mammary glands
in animal models (31–33). Estrogen-like
effects of phytoestrogens have also been
observed in humans, including increased
bone density, alleviation of postmenopausal
symptoms, and effects on the breast (34,35).
The reports on antiestrogenic effects are less
clear, but antiestrogen-like effects have been
observed when phytoestrogens were admin-
istered together with potent estrogens to
immature or ovariectomized female animals,
where the phytoestrogens decreased the
uterotropic effect of the potent estrogen
(31,32). This could have been caused by aro-
matase inhibition because the aromatase is
expressed in the uterus (36), and inhibition
would thus lead to a reduced intracrine
estradiol synthesis that subsequently must be
“subtracted” from the estrogenic response
induced by the administered potent estro-
gens (31,32). Antiestrogenic effects were also
observed on the prostate of male mice treated
with diethylstilbestrol (DES), where phyto-
estrogens reduced the dysplastic changes
induced by DES (31). As described above,
this may be the result of aromatase inhibition
because the aromatase is expressed in the
prostate (37), and aromatase inhibitors seem
to have similar effects (38). The evidence for
antiestrogenic properties in vitro is scarce.
However, a recent report suggested that
some phytoestrogens, glyceollins, have anti-
estrogenic properties because they reduced
the estrogenic response when they were
added to the culture medium together with
17β-estradiol (5). We have not tested any
glyceollins in our assay, and their putative
aromatase inhibitory properties are not
known. However, the design of the assay in
Burow et al. (5) suggests that glyceollins do
posess antiestrogenic properties because the
effect most probably cannot be explained by
aromatase inhibition.
Another possible example of in vivo aro-
matase inhibition is the protective effects of
phytoestrogens against breast cancer that has
been demonstrated both experimentally and
by epidemiology (34,39–41). Breast cancer is
often treated with aromatase inhibitors
because the intracrine estradiol production in
tumor cells is more important for prolifera-
tion of estrogen-dependent breast cancer cells
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Table 1. Estrogenicity and aromatase inhibitory properties of the tested compounds.
Aromatase inhibitor at low 
Compound Estrogenic concentration
Phytoestrogens
Biochanin A Yes Yes
Genisteina Yes No
Formononetinb Yes Yes
Naringenin Yes Yes
Chrysin Yes Yes
Red clover ﬂowersc Yes Yes
Synthetic chemicals
Nonylphenol Yes No
Bisphenol A Yes No
Dibutylphthalate Yes No
Dieldrin Yes No
Aromatase inhibitors
Anastrozole No Yes
4-Hydroxy-4-androstene-3,17-dione No Yes
aNot aromatase inhibitor in humans (19). bAromatase inhibition was not detected by Le Bail et al. (3). cDried powder sus-
pended at 10% (w/v) in ethanol; red clover ﬂower is a rich source of biochanin A.
Figure 4. Dose–response curves for selected
compounds. Abbreviations: 4OHA, 4-hydroxy-4-
androstene-3,17-dione; T, testosterone. The val-
ues represent the expression levels of the pS2
mRNA after incubation with the indicated con-
centrations of the compounds. The values are rel-
ative to the response from 100 nM T. Each value
without error bars corresponds to the mean of
two samples; otherwise, each point represents
the mean of four independent samples, and error
bars indicate SEM. Dilutions of the 10% w/v red
clover suspension were between 10–3- (highest
concentration) and 10–7-fold.
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Concentrationthan are serum 17β-estradiol levels (11). In
fact, treatment with aromatase inhibitors was
more effective than treatment with antiestro-
gens, emphasizing the importance of the
intracrine estradiol production (42). The aro-
matase inhibition by biochanin A in MCF-7
breast cancer cells was only about one order
of magnitude less than that of an aromatase
inhibitor used with benefit in breast cancer
treatment (Anastrozole) (42,43) (Figure 3),
and it occurred at concentrations that have
been observed for phytoestrogens in humans
(44). Therefore, we suggest that a major part
of the observed beneficial effect of phyto-
estrogens on breast cancer most likely is due
to their aromatase inhibitory properties.
Like pharmaceutical aromatase inhibitors
(45), phytoestrogens may affect humans and
animals differently, depending on the age
when the exposure occurs. Several reports
describe adverse effects with in utero or peri-
natal exposure, including a higher prevalence
of malformed genitalia in boys born from
vegetarians, and evidence for cancer-promot-
ing effects in rodents (46–48). The apparent
differential effects may correlate with the
intracrine estradiol production: In children
and fetuses with low estradiol production,
aromatase inhibition cannot counteract a
high exposure by lowering the estradiol pro-
duction because it is already very low, and
they therefore experience adverse effects. In
adults, phytoestrogens reduce the intracrine
estradiol production, which thereby com-
pensates for the exposure. The same could
be the case for tissues with and without
intracrine estradiol production. Sensitivity of
the aromatase to inhibition by phytoestro-
gens could even be an evolutionary adapta-
tion to an occasional high exposure to
phytoestrogens because such a mechanism
would protect against a dangerously high
estrogenicity level by reducing the intracrine
estradiol synthesis.
Conclusions
Based on our study, we conclude that MCF-7
cells can be used for identifying aromatase
inhibitors. Phytoestrogens act as aromatase
inhibitors at low concentrations and are estro-
genic at higher concentrations, resulting in U-
shaped dose–response curves. Aromatase
inhibition may partly explain previous reports
about antiestrogenicity of phytoestrogens, and
low-concentration aromatase inhibition most
likely contributes to the cancer-protecting
properties of phytoestrogens.
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